HLA-C and neoplasm: Hence, a better knowledge of the “immunopeptidome” (the repertoire of peptides bound to and presented by MHC molecules) and how tumor-specific antigen repertoire change during tumor progression is expected to improve the current therapeutic strategies; thus, a challenging issue is the identification and characterization of the MHC-I-presented peptides that modulate T cell-based tumor response [12,13,14].